Enjoy complimentary customisation on priority with our Enterprise License!
The diffuse large B-cell lymphoma (DLBCL) therapeutics market is estimated to increase by USD 2,061.88 million between 2022 and 2027. The size of the market is forecast to grow at a CAGR of 7.96%. The growth of the market depends on several factors, including the growing geriatric population, increasing incidence, and increasing approval of therapeutics for patients with relapsed or refractory DLBCL.
To learn more about this report, Download Report Sample
The increasing approval of therapeutics for patients with relapsed or refractory DLBCL is notably driving the market growth, although factors such as the high cost of the treatment may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Key Driver
The increasing approval of therapeutics for patients with relapsed or refractory DLBCL is notably driving market growth. Market players are focusing on regulatory approvals for therapeutics for patients with relapsed or refractory DLBCL, which is expected to fuel market growth. For instance, in February 2021, Bristol Myers Squibb, a pharmaceutical company, received approval for lisocabtagene maraleucel (liso-cel, Breyanzi), chimeric antigen receptor (CAR) T-cell therapy, indicated for diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and follicular lymphoma grade 3B, in patients who have not responded to, or who have relapsed after, at least two other types of systemic treatment.
Similarly, in November 2020, ADC Therapeutics SA, a late clinical-stage biotechnology company, announced that its Biologics License Application (BLA) for loncastuximab tesirine (Lonca) had been accepted by the US Food and Drug Administration (FDA). Lloncastuximab tesirine (Lonca) is being developed for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Hence, such developments will drive the growth of the global diffuse large B-Cell lymphoma therapeutics market during the forecast period.
Significant Trend
Technological advances are an emerging trend in market growth. Companies are focusing on developing new technologies and innovative therapies that can overcome the current challenges in the treatment of various cancers, including DLBCL. Currently, many technological advances, such as chimeric antigen receptor (CAR) T-cell therapy, gene therapy, companion diagnostics, and personalized medicines, are being developed at a very rapid pace.
Technological advances increase the efficacy of products and invent highly effective drugs for the treatment of various diseases. Through such technological advances, industry-focused players such as Novartis and Gilead and diversified players such as F. Hoffmann-La Roche are focusing on CAR T-cell therapy and gene therapy. These new therapy areas are more effective and reduce the efforts in the treatment. Therefore, factors like these will fuel the growth of the global diffuse large B-Cell lymphoma therapeutics market during the forecast period.
Major Challenge
The high cost of DLBCL treatment is a major challenge impeding the market growth. The high treatment cost associated with cancer is the most important cause of concern for patients. Drugs such as vincristine, doxorubicin, and either prednisone or bortezomib may help some patients with advanced DLBCL, which are associated with high costs. Chemotherapy also needs to be continued for a substantial period for the long-term survival of the patient, which further adds to the cost of the treatment. Also, as per the NCBI, the probability of recurrent or relapsed DLBCL is up to 30% of cases worldwide. Hence, treating advanced-stage NHL, particularly this treatment, becomes expensive.
Furthermore, the cost of biologics available for the treatment of DLBCL THERAPEUTICS is high. Moreover, the inadequate distribution network of drugs in underdeveloped and developing economies is resulting in high distribution costs, which increases the cost of DLBCL therapeutics further. Although developed markets such as the US, Canada, the UK, and Germany have strong healthcare systems, the prices of the available drugs are substantially high. Therefore, factors like these will hinder the growth of the global diffuse large B-Cell lymphoma therapeutics market during the forecast period.
Key Market Customer Landscape
The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Amgen Inc. - The company focuses on discovering, developing, manufacturing, and delivering innovative human therapeutics. The key offerings of the company include diffuse large B-cell lymphoma therapeutics.
The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market share growth by the hospital pharmacy segment will be significant during the forecast period. Hospital pharmacies play an important role in the management, as they are responsible for the storage, preparation, and dispensing of DLBCL therapeutics to patients. DLBCL therapeutics are often administered in a hospital or clinical setting, and hospital pharmacists are typically involved in the management of these treatments, including monitoring patients for adverse effects and drug interactions.
Get a glance at the market contribution of various segments Request a PDF Sample
The hospital pharmacy segment was valued at USD 1,438.58 million in 2017 and continued to grow until 2021. The hospital pharmacy segment is a significant part of the DLBCL therapeutics market, as many of these treatments are administered in a hospital or clinical setting. Hospital pharmacies are responsible for ensuring the safe and effective use of DLBCL therapeutics, which includes proper storage, preparation, and dispensing of these medications to patients. They also play a crucial role in monitoring patients for adverse effects and drug interactions, providing education to patients, and working closely with healthcare providers to ensure the best possible care for patients with DLBCL. Hence, owing to such advantages the DLBCL therapeutics market segment will register growth during the forecast period.
For more insights on the market share of various regions Request PDF Sample now!
North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The growth of the market in this region is primarily driven by the sales of approved therapeutics for the treatment of various subtypes of NHL and the increasing prevalence of various cancer types, including DLBCL. According to the National Program of Cancer Registries (NPCR), which is carried out by the Centers for Disease Control and Prevention (CDC), more than 28.5 million invasive cancer cases have been diagnosed in the last two decades. NHL is the eighth-most prevalent type of cancer in the US, which is the reason for the country being a major contributor to the market in North America. According to the CDC, in 2021, the prevalence of DLBCL in the US was 22% per 100,000 people. Such a high prevalence of the disease demands advanced and specialized treatment options. Targeted therapies, such as VELCADE and CALQUENCE, have the potential to meet this requirement. Hence, the high prevalence of DLBCL is expected to drive the growth of the market in North America during the forecast period.
Although the US has various approved therapies for the treatment of DLBCL, the cost of most of these target-specific drugs is high. The high cost of these drugs is a potential challenge for the market, and patient assistance programs offset this challenge to a great extent. For instance, Johnson and Johnson provides a patient assistance program. Under this program, the company provides eligible patients with free prescription medicines. The assistance includes contacting patients' insurance providers to help patients understand their coverage. Thus, the increasing prevalence of DLBCL and the availability of targeted therapies and patient assistance programs are expected to support the growth of the DLBCL therapeutics market in North America during the forecast period.
The market is witnessing significant advancements driven by patient awareness, collaborative initiatives, and evolving standards of care. Biomarker discovery and immunotherapy innovations are revolutionizing treatment approaches. Incidence rates are spurring healthcare infrastructure development, enhancing access to novel drugs in outpatient settings. Collaborative clinical trials and patient-centric care models are shaping treatment paradigms. Diagnostic imaging advances aid in early diagnosis, while healthcare digitalization improves patient management. DLBCL prevalence underscores the importance of genetic and molecular profiling for personalized treatment strategies. Conventional RCHOP therapy remains pivotal, alongside diagnostic devices, radiation therapy equipment, and surgical instruments. The market's trajectory reflects a concerted effort towards improving outcomes and addressing the evolving needs of DLBCL patients.
The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Market Scope |
|
Report Coverage |
Details |
Page number |
166 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7.96% |
Market growth 2023-2027 |
USD 2,061.88 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
7.13 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 46% |
Key countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., ADC Therapeutics SA, Amgen Inc., Bayer AG, BeiGene Ltd., Bristol Myers Squibb Co., Celltrion Healthcare Co. Ltd., CTI BioPharma Corp., Erytech Pharma SA, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Pfizer Inc., Seagen Inc., Spectrum Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd. |
Market dynamics |
Parent market analysis, Market forecasting, market growth and trends, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our market research report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.